van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R
Department of Intensive Care Medicine, Catholic University of Leuven, Belgium.
N Engl J Med. 2001 Nov 8;345(19):1359-67. doi: 10.1056/NEJMoa011300.
Hyperglycemia and insulin resistance are common in critically ill patients, even if they have not previously had diabetes. Whether the normalization of blood glucose levels with insulin therapy improves the prognosis for such patients is not known.
We performed a prospective, randomized, controlled study involving adults admitted to our surgical intensive care unit who were receiving mechanical ventilation. On admission, patients were randomly assigned to receive intensive insulin therapy (maintenance of blood glucose at a level between 80 and 110 mg per deciliter [4.4 and 6.1 mmol per liter]) or conventional treatment (infusion of insulin only if the blood glucose level exceeded 215 mg per deciliter [11.9 mmol per liter] and maintenance of glucose at a level between 180 and 200 mg per deciliter [10.0 and 11.1 mmol per liter]).
At 12 months, with a total of 1548 patients enrolled, intensive insulin therapy reduced mortality during intensive care from 8.0 percent with conventional treatment to 4.6 percent (P<0.04, with adjustment for sequential analyses). The benefit of intensive insulin therapy was attributable to its effect on mortality among patients who remained in the intensive care unit for more than five days (20.2 percent with conventional treatment, as compared with 10.6 percent with intensive insulin therapy, P=0.005). The greatest reduction in mortality involved deaths due to multiple-organ failure with a proven septic focus. Intensive insulin therapy also reduced overall in-hospital mortality by 34 percent, bloodstream infections by 46 percent, acute renal failure requiring dialysis or hemofiltration by 41 percent, the median number of red-cell transfusions by 50 percent, and critical-illness polyneuropathy by 44 percent, and patients receiving intensive therapy were less likely to require prolonged mechanical ventilation and intensive care.
Intensive insulin therapy to maintain blood glucose at or below 110 mg per deciliter reduces morbidity and mortality among critically ill patients in the surgical intensive care unit.
高血糖和胰岛素抵抗在重症患者中很常见,即使他们之前没有患过糖尿病。胰岛素治疗使血糖水平正常化是否能改善这类患者的预后尚不清楚。
我们进行了一项前瞻性、随机、对照研究,纳入入住我院外科重症监护病房并接受机械通气的成年患者。入院时,患者被随机分配接受强化胰岛素治疗(将血糖维持在80至110毫克每分升[4.4至6.1毫摩尔每升]之间)或常规治疗(仅当血糖水平超过215毫克每分升[11.9毫摩尔每升]时输注胰岛素,并将血糖维持在180至200毫克每分升[10.0至11.1毫摩尔每升]之间)。
在12个月时,共纳入1548例患者,强化胰岛素治疗使重症监护期间的死亡率从常规治疗的8.0%降至4.6%(经序贯分析调整后,P<0.04)。强化胰岛素治疗的益处归因于其对在重症监护病房停留超过五天的患者死亡率的影响(常规治疗为20.2%,强化胰岛素治疗为10.6%,P = 0.005)。死亡率下降最大的是因有明确感染灶的多器官功能衰竭导致的死亡。强化胰岛素治疗还使总体住院死亡率降低了34%,血流感染降低了46%,需要透析或血液滤过的急性肾衰竭降低了41%,红细胞输注中位数降低了50%,重症多神经病降低了44%,接受强化治疗的患者需要长时间机械通气和重症监护的可能性较小。
强化胰岛素治疗将血糖维持在110毫克每分升或以下可降低外科重症监护病房中重症患者的发病率和死亡率。